Non-Alcoholic Fatty Liver Disease Diagnosis and Management
Epidemiology and Prevalence
- Non-alcoholic fatty liver disease (NAFLD) represents the leading cause of chronic liver disease worldwide, with a prevalence of 20-30% in the general population, increasing to 70% with obesity and 90% with diabetes mellitus 1
- NAFLD is the most common cause of elevated liver function tests in developed countries, accounting for approximately 26% of incidental LFT abnormalities in primary care settings 1
Clinical Pattern Recognition
- NAFLD typically presents with mild aminotransferase elevations (<5 times upper reference limit), with ALT and AST being the predominant elevated enzymes 1
- The AST:ALT ratio in NAFLD is typically <1, which distinguishes it from alcohol-induced liver disease where the ratio is generally >2 1, 2
- Common causes of mild aminotransferase increases include NAFLD and alcohol-induced liver disease, with uncommon causes being drug-induced liver injury, hepatitis B, hepatitis C, and hereditary hemochromatosis 1
Differential Diagnosis Framework
- Presence of metabolic risk factors, such as obesity, type 2 diabetes, insulin resistance, and metabolic syndrome, makes NAFLD more likely 1, 3
- An AST:ALT ratio <1 and mild to moderate aminotransferase elevations are also suggestive of NAFLD 1, 2
- Alcohol-induced liver disease is more likely with an AST:ALT ratio >2, elevated GGT, and alcohol consumption >20 g/day in females or >30 g/day in males 1, 2, 4
Critical Clinical Pitfalls
- The magnitude of LFT abnormality does not correlate with disease severity or prognosis, and patients with significant liver fibrosis may have liver enzymes in the normal reference range 3
- Do not assume normal LFTs exclude significant liver disease, as many patients with advanced fibrosis have normal liver enzymes and synthetic function 3
- Approximately 20% of patients with alcohol use disorder and abnormal LFTs have a co-existing etiology requiring further investigation 4